Lineage Cell Therapeutics Share Price (NYSE: LCTX)

$1.18

▲

-0.03

(-2.48%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Lineage Cell Therapeutics Stock chart to analyse performance

Lineage Cell Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$1.16
Today's High:$1.23
$1.18
1.69%
Downside
Day's Volatility :5.31%
Upside
3.67%
52 Weeks Low:$0.37
52 Weeks High:$1.31
$1.18
69.06%
Downside
52 Weeks Volatility :72.13%
Upside
9.92%

Lineage Cell Therapeutics Stock Returns

Period	Lineage Cell Therapeutics Inc	Index (Russel 2000)
3 Months	76.69%	0.0%
6 Months	130.35%	0.0%
1 Year	34.29%	0.0%
3 Years	-15.47%	-4.7%

Lineage Cell Therapeutics Inc Key Stats

Check Lineage Cell Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.21
Open	$1.225
Today's High	$1.225
Today's Low	$1.16
Market Capitalization	$278.6M
Today's Volume	$988.8K
52 Week High	$1.31
52 Week Low	$0.3651
Revenue TTM	$10.9M
EBITDA	$-19.8M
Earnings Per Share (EPS)	$-0.17
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-71.51%

Stock Returns calculator for Lineage Cell Therapeutics Stock including INR - Dollar returns

The Lineage Cell Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Lineage Cell Therapeutics investment value today

Current value as on today

₹1,39,375

Returns

₹39,375

(+39.38%)

Returns from Lineage Cell Therapeutics Stock

₹34,091 (+34.09%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Lineage Cell Therapeutics Stock

17%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Lineage Cell Therapeutics Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Lineage Cell Therapeutics Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Lineage Cell Therapeutics(by analysts ranked 0 to 5 stars)

Lineage Cell Therapeutics Share Price Target

What analysts predicted

Upside of 253.11%

Target:

$4.17

Current:

$1.18

Lineage Cell Therapeutics share price target is $4.17, a slight Upside of 253.11% compared to current price of $1.18 as per analysts' prediction.

Lineage Cell Therapeutics Stock Insights

Price Movement
In the last 3 months, LCTX stock has moved up by 76.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.50M → 2.76M (in $), with an average increase of 45.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -3.03M → -30.46M (in $), with an average decrease of 223.5% per quarter
LCTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 37.0%
LCTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 130.4%
Price to Sales
ForLCTX every $1 of sales, investors are willing to pay $24.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Lineage Cell Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.5M	↑ 4.38%
Net Income	$-11.8M	↓ 74.28%
Net Profit Margin	-800.2%	↑ 2447.68%

	FY20	Y/Y Change
Revenue	$773.0K	↓ 47.7%
Net Income	$-20.7M	↑ 74.9%
Net Profit Margin	-2.7K%	↓ 1875.74%

	FY21	Y/Y Change
Revenue	$3.9M	↑ 404.01%
Net Income	$-43.0M	↑ 107.97%
Net Profit Margin	-1.1K%	↑ 1571.76%

	FY22	Y/Y Change
Revenue	$14.7M	↑ 277.39%
Net Income	$-26.4M	↓ 38.74%
Net Profit Margin	-179.24%	↑ 924.94%

	FY23	Y/Y Change
Revenue	$8.9M	↓ 39.16%
Net Income	$-21.5M	↓ 18.47%
Net Profit Margin	-240.2%	↓ 60.96%

	FY24	Y/Y Change
Revenue	$9.5M	↑ 6.19%
Net Income	$-18.6M	↓ 13.39%
Net Profit Margin	-195.9%	↑ 44.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.4M	↓ 30.84%
Net Income	$-6.5M	↑ 37.01%
Net Profit Margin	-453.05%	↓ 224.36%

	Q2 FY24	Q/Q Change
Revenue	$1.4M	↓ 2.49%
Net Income	$-5.8M	↓ 11.95%
Net Profit Margin	-409.09%	↑ 43.96%

	Q3 FY24	Q/Q Change
Revenue	$3.8M	↑ 168.39%
Net Income	$-3.0M	↓ 47.33%
Net Profit Margin	-80.29%	↑ 328.8%

	Q4 FY24	Q/Q Change
Revenue	$2.9M	↓ 24.11%
Net Income	$-3.3M	↑ 7.88%
Net Profit Margin	-114.12%	↓ 33.83%

	Q1 FY25	Q/Q Change
Revenue	$1.5M	↓ 47.63%
Net Income	$-4.1M	↑ 26.46%
Net Profit Margin	-275.57%	↓ 161.45%

	Q2 FY25	Q/Q Change
Revenue	$2.8M	↑ 84.09%
Net Income	$-30.5M	↑ 636.02%
Net Profit Margin	-1.1K%	↓ 826.2%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.1M	↓ 4.31%

	FY20	Y/Y Change
Profit	$388.0K	↓ 63.6%

	FY21	Y/Y Change
Profit	$2.5M	↑ 536.6%

	FY22	Y/Y Change
Profit	$14.0M	↑ 465.79%

	FY23	Y/Y Change
Profit	$8.3M	↓ 40.79%

	FY24	Y/Y Change
Profit	$9.2M	↑ 10.77%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.2M	↓ 29.33%

	Q2 FY24	Q/Q Change
Profit	$1.4M	↑ 16.48%

	Q3 FY24	Q/Q Change
Profit	$3.7M	↑ 174.27%

	Q4 FY24	Q/Q Change
Profit	$2.7M	↓ 27.45%

	Q1 FY25	Q/Q Change
Profit	$1.5M	↓ 45.98%

	Q2 FY25	Q/Q Change
Profit	$2.7M	↑ 85.95%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-31.9M	↑ 3.45%
Investing Cash Flow	$17.0M	↑ 43.51%
Financing Cash Flow	$617.0K	↓ 89.31%

	FY20	Y/Y Change
Operating Cash Flow	$-19.8M	↓ 38.17%
Investing Cash Flow	$13.0M	↓ 23.11%
Financing Cash Flow	$29.9M	↑ 4740.36%

	FY21	Y/Y Change
Operating Cash Flow	$-23.6M	↑ 19.28%
Investing Cash Flow	$9.7M	↓ 25.26%
Financing Cash Flow	$36.9M	↑ 23.66%

	FY22	Y/Y Change
Operating Cash Flow	$1.1M	↓ 104.49%
Investing Cash Flow	$-46.2M	↓ 573.67%
Financing Cash Flow	$1.6M	↓ 95.58%

	FY23	Y/Y Change
Operating Cash Flow	$-28.6M	↓ 2797.45%
Investing Cash Flow	$46.4M	↓ 200.63%
Financing Cash Flow	$6.4M	↑ 293.57%

	FY24	Y/Y Change
Operating Cash Flow	$-23.1M	↓ 19.16%
Investing Cash Flow	$-2.3M	↓ 104.97%
Financing Cash Flow	$35.9M	↑ 458.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-5.8M	↓ 3.92%
Investing Cash Flow	$-38.0K	↓ 100.39%
Financing Cash Flow	$14.0M	↓ 107953.85%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-5.2M	↓ 10.5%
Investing Cash Flow	$-8.8M	↑ 23039.47%
Financing Cash Flow	$105.0K	↓ 99.25%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-5.8M	↑ 11.8%
Investing Cash Flow	$3.9M	↓ 144.22%
Financing Cash Flow	$-3.0K	↓ 102.86%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-6.3M	↑ 9.66%
Investing Cash Flow	$2.6M	↓ 32.23%
Financing Cash Flow	$21.7M	↓ 724566.67%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-4.9M	↓ 23.01%
Investing Cash Flow	$1.9M	↓ 27.78%
Financing Cash Flow	$5.0M	↓ 76.79%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-5.5M	↑ 13.36%
Investing Cash Flow	$-14.0K	↓ 100.74%
Financing Cash Flow	$-307.0K	↓ 106.09%

Lineage Cell Therapeutics Technicals Summary

Sell

Neutral

Buy

Lineage Cell Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Lineage Cell Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lineage Cell Therapeutics Inc	15.2%	130.35%	34.29%	-15.47%	32.62%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lineage Cell Therapeutics Inc	NA	NA	NA	-0.19	-0.72	-0.13	NA	0.21
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lineage Cell Therapeutics Inc	Buy	$278.6M	32.62%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Organization	Lineage Cell Therapeutics
Employees	70
CEO	Dr. Rami Skaliter Ph.D.
Industry	Health Technology

Key Management of Lineage Cell Therapeutics Inc

Name	Title
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary
Ms. Ioana C. Hone	Director of Investor Relations
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences
Ms. Alexandra Hernandez	Senior Director of Finance & Controller
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control

Important FAQs about investing in LCTX Stock from India :

What is Lineage Cell Therapeutics share price today?

Lineage Cell Therapeutics share price today is $1.18 as on August 30, 2025 at 1:29 am IST at the close of the market. Lineage Cell Therapeutics share today touched a day high of $1.23 and a low of $1.16.

What is the 52 week high and 52 week low for Lineage Cell Therapeutics share?

Lineage Cell Therapeutics share touched a 52 week high of $1.31 and a 52 week low of $0.37. Lineage Cell Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $1.18, lower by 9.92% versus the 52 week high.

How to invest in Lineage Cell Therapeutics Stock (LCTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Lineage Cell Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lineage Cell Therapeutics Shares that will get you 1.2712 shares as per Lineage Cell Therapeutics share price of $1.18 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Lineage Cell Therapeutics Stock (LCTX) from India?

Indian investors can start investing in Lineage Cell Therapeutics (LCTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Lineage Cell Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Lineage Cell Therapeutics share’s latest price of $1.18 as on August 30, 2025 at 1:29 am IST, you will get 8.4746 shares of Lineage Cell Therapeutics. Learn more about fractional shares .

What are the returns that Lineage Cell Therapeutics has given to Indian investors in the last 5 years?

Lineage Cell Therapeutics stock has given 32.62% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?